Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $9.2 million.

  • Anaptysbio's Share-based Compensation rose 1182.07% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 522.44%. This contributed to the annual value of $34.0 million for FY2024, which is 253.88% up from last year.
  • According to the latest figures from Q3 2025, Anaptysbio's Share-based Compensation is $9.2 million, which was up 1182.07% from $9.2 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Share-based Compensation registered a high of $10.1 million during Q1 2024, and its lowest value of $3.3 million during Q1 2021.
  • In the last 5 years, Anaptysbio's Share-based Compensation had a median value of $7.8 million in 2023 and averaged $7.2 million.
  • In the last 5 years, Anaptysbio's Share-based Compensation soared by 13354.45% in 2022 and then tumbled by 1047.82% in 2024.
  • Anaptysbio's Share-based Compensation (Quarter) stood at $4.0 million in 2021, then surged by 68.05% to $6.7 million in 2022, then grew by 21.33% to $8.1 million in 2023, then increased by 0.9% to $8.2 million in 2024, then grew by 11.89% to $9.2 million in 2025.
  • Its Share-based Compensation was $9.2 million in Q3 2025, compared to $9.2 million in Q2 2025 and $9.2 million in Q1 2025.